Lake Street keeps AVITA Medical at Buy and lifts price target to $20
Lake Street kept its Buy rating on AVITA Medical and raised its price target from $12 to $20, according to TradingView, with the Nov 6 close at $16.59.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, analysts at Lake Street maintained their Buy rating on AVITA Medical shares and raised the price target from $12 to $20, a 66.7% increase.
The new target implies an upside of about 20.6% from the Nov 6 close of $16.59. More price target data and ratings are available on the TradingView website, with reference data provided by Benzinga.
why it matters
For the market this is a routine event: a single analyst revising its target usually has only a short-term effect on the stock and does not signal a broader shift in the sector. Such estimates reflect one firm's view and are not investment advice.
tags
instruments
sources
- Lake Street maintains AVITA Medical at Buy, raises price target to $20 from $12 — TradingView, 7 November 2026 at 01:33 UTC
- Lake Street maintains Arlo Technologies at Buy, raises price target to $26 from $25 — TradingView, 7 November 2026 at 01:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗